Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, University of Kentucky to Collaborate on Ovarian Cancer Dx

NEW YORK, AUG, 24 (GenomeWeb News) - Ciphergen Biosystems and the University of Kentucky have signed a research and collaboration agreement that will allow the Ciphergen to exclusively license discoveries from partnership's ovarian cancer research for use in diagnostics, Ciphergen said today.

 

According to Paul DePriest, an associate professor of obstetrics and gynecology at UK, the university hopes that the partnership will "accelerate the development of a new diagnostic approach to ovarian cancer" by pairing UK's clinical expertise with Ciphergen's "biomarker discovery and diagnostic process."

 

Ciphergen will be providing UK with its suite of proteomic tools to help researchers analyze patients' tumor cyst fluid and blood for biomarker discovery and development of assays, the company said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.